Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.

Transplant infectious disease : an official journal of the Transplantation Society - 1 Feb 2018

Vitrone Martina, Andini Roberto, Mattucci Irene, Maiello Ciro, Atripaldi Luigi, Durante-Mangoni Emanuele, Zampino Rosa

Abstract excerpt

Direct-acting antiviral agents (DAAs) are a safe and effective treatment for chronic hepatitis C (CHC). This may be particularly valuable for patients with severe comorbidities or baseline conditions, including non-liver solid organ transplant. We report cases of two heart transplant recipients with CHC treated with DAAs (sofosbuvir and daclatasvir) achieving sustained virological response. Treatment was well...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Comorbidity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Heart Transplantation

Share to Hepatitis C, Chronic

Share to Ribavirin

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Identifiers

PMID: 29139181
DOI: 10.1111/tid.12813

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.PMID 29139181Read ↗

Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Semantic proximity Read ↗

A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.Semantic proximity Read ↗

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Semantic proximity Read ↗

Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.Semantic proximity Read ↗

Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.Semantic proximity Read ↗

Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.Semantic proximity Read ↗

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.Semantic proximity Read ↗

Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.Semantic proximity Read ↗

Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals.Semantic proximity Read ↗

High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam.Semantic proximity Read ↗

Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.Semantic proximity Read ↗

Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.